Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 8.4% – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares fell 8.4% during trading on Thursday . The stock traded as low as $23.50 and last traded at $23.0150. 2,582 shares traded hands during trading, a decline of 17% from the average session volume of 3,113 shares. The stock had previously closed at $25.13.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AAPG. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research note on Friday. They set a “buy” rating and a $40.00 price target on the stock. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Price Performance

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The stock’s 50-day simple moving average is $24.43 and its two-hundred day simple moving average is $28.04.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. Equities analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the last quarter. XY Capital Ltd grew its position in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International in the 2nd quarter worth $391,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the 3rd quarter worth $383,000. Finally, ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the 3rd quarter worth $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.